Drugs / Upamostat
Upamostat
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT05954286 | Jan 2024 → Apr 2025 | COVID-19 | Henry M. Jackson Foundation for the Advancement of Military Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00615940 | Jul 2008 → Dec 2011 | Her2-receptor negative breast cancer | Heidelberg Pharma AG | Completed | No outcome recorded |
| Phase 2 | NCT00499265 | Apr 2007 → May 2010 | malignant pancreatic neoplasm | Heidelberg Pharma AG | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT04723537 | Feb → Dec 2021 | COVID-19 | RedHill Biopharma Limited | Terminated | Met primary |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | RedHill Biopharma Limited | Regulatory RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107 redhillbio.com ↗
today announced that the China National Intellectual Property Administration ("CNIPA") has formally allowed a critical use of composition-of-matter patent for RedHill's proprietary investigational compound RHB-107 (upamostat), a potential oral treatment for COVID-19 (patent application No. 202311591091.6). |
| 2023-12-20 | RedHill Biopharma Limited | Results RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola redhillbio.com ↗
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its two novel, oral host-directed investigational drugs, opaganib[1] and RHB-107 (upamostat)[2], demonstrated robust synergistic effect when combined individually with remdesivir (Veklury®)[3], significantly improving viral inhibition while maintaining cell viability, in a new U.S. Army-funded and conducted Ebola virus in vitro study. |
| 2023-12-04 | RedHill Biopharma Limited | Regulatory RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study redhillbio.com ↗
In addition to the platform's Master Protocol, the 300-patient Phase 2 RHB-107 arm has received FDA clearance to start, with the first patient expected to be enrolled in the coming weeks. |
| 2023-07-31 | RedHill Biopharma Limited | Regulatory RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA redhillbio.com ↗ |
| 2023-01-03 | RedHill Biopharma Limited | Results RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19 redhillbio.com ↗
The study showed that RHB-107 successfully met the primary endpoint of safety and tolerability and delivered promising efficacy results, despite the small number of patients in each treatment group, including faster recovery from severe COVID-19 symptoms and 100% reduction in hospitalization due to COVID-19. |
| 2022-10-03 | RedHill Biopharma Limited | Results RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5 redhillbio.com ↗ |
| 2022-03-01 | RedHill Biopharma Limited | Results RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19 redhillbio.com ↗
Phase 2 part of Phase 2/3 study of once-daily oral RHB-107 in symptomatic COVID-19 successfully met the study's primary endpoint showing good safety and tolerability and highly promising efficacy results |
| 2021-09-13 | RedHill Biopharma Limited | Regulatory RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval redhillbio.com ↗
The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care |
| 2021-05-26 | RedHill Biopharma Limited | Regulatory RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 redhillbio.com ↗
today announced receipt of two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) covering opaganib1 and RHB-107 (upamostat)2 as methods for the treatment of COVID-19 caused by the SARS-CoV-2 virus. |
| 2020-11-17 | RedHill Biopharma Limited | Regulatory RedHill Biopharma’s Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease redhillbio.com ↗ |
| 2020-09-08 | RedHill Biopharma Limited | Results RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2 redhillbio.com ↗
RedHill’s second COVID-19 drug candidate, RHB-107 (upamostat), a novel serine protease inhibitor, strongly inhibited SARS-CoV-2 viral replication in the same model, further supporting planned initiation of a Phase 2/3 U.S. outpatient study later this year |
| 2017-10-20 | RedHill Biopharma Limited | Regulatory RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer redhillbio.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has granted MESUPRON (upamostat) Orphan Drug designation for the adjuvant treatment of pancreatic cancer. |
All press releases naming this drug 14 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Upamostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04723537 ↗ |
| Known as | Mesupron | ChEMBL registry synonym — accepted as the source's own label CHEMBL4206119 ↗ |
| Known as | WX-671 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00615940 ↗ |
| Known as | WX-671.1 | “Upamostat is available as a hydrogen sulphate salt (also designated as WX-671.1).” NCT05954286 ↗ |
| Action | Inhibit | “WX-671 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT00499265 ↗ |
| Modality | Small molecule | — CHEMBL4206119 ↗ |
| Route | Oral | “Patients receive oral anti-uPA serine protease inhibitor WX-671” NCT00499265 ↗ |